Gestational trophoblastic disease

R. S. Freedman, G. Tortolero-Luna, D. K. Pandey, A. Malpica, V. V. Baker, L. Whittaker, E. Johnson, M. F. Mitchell

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

GTD occurs in fewer than 1 in 1200 pregnancies in the United States, but it is much more common in Asia and Latin America, where its incidence may be as high as 1 in 200 pregnancies. Risk factors for GTD include advanced or young maternal age, low socioeconomic status, and prior hydatidiform mole. Early diagnosis and prompt treatment are key to a favorable outcome, and thus recognition of the signs and symptoms of the disease is important for all physicians. Because these diseases have low incidences and occur after reproductive events, screening for them in the general population is not worthwhile. No chemopreventive agents have yet been studied in women at risk for GTD, but the oral contraceptive is a good candidate.

Original languageEnglish (US)
Pages (from-to)545-571
Number of pages27
JournalObstetrics and Gynecology Clinics of North America
Volume23
Issue number2
StatePublished - Jul 1 1996

Fingerprint

Gestational Trophoblastic Disease
Hydatidiform Mole
Pregnancy
Latin America
Incidence
Maternal Age
Oral Contraceptives
Social Class
Signs and Symptoms
Early Diagnosis
Physicians
Population
Therapeutics

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Freedman, R. S., Tortolero-Luna, G., Pandey, D. K., Malpica, A., Baker, V. V., Whittaker, L., ... Mitchell, M. F. (1996). Gestational trophoblastic disease. Obstetrics and Gynecology Clinics of North America, 23(2), 545-571.

Gestational trophoblastic disease. / Freedman, R. S.; Tortolero-Luna, G.; Pandey, D. K.; Malpica, A.; Baker, V. V.; Whittaker, L.; Johnson, E.; Mitchell, M. F.

In: Obstetrics and Gynecology Clinics of North America, Vol. 23, No. 2, 01.07.1996, p. 545-571.

Research output: Contribution to journalReview article

Freedman, RS, Tortolero-Luna, G, Pandey, DK, Malpica, A, Baker, VV, Whittaker, L, Johnson, E & Mitchell, MF 1996, 'Gestational trophoblastic disease', Obstetrics and Gynecology Clinics of North America, vol. 23, no. 2, pp. 545-571.
Freedman RS, Tortolero-Luna G, Pandey DK, Malpica A, Baker VV, Whittaker L et al. Gestational trophoblastic disease. Obstetrics and Gynecology Clinics of North America. 1996 Jul 1;23(2):545-571.
Freedman, R. S. ; Tortolero-Luna, G. ; Pandey, D. K. ; Malpica, A. ; Baker, V. V. ; Whittaker, L. ; Johnson, E. ; Mitchell, M. F. / Gestational trophoblastic disease. In: Obstetrics and Gynecology Clinics of North America. 1996 ; Vol. 23, No. 2. pp. 545-571.
@article{11145b0119f44e2590eb7f9871b5630a,
title = "Gestational trophoblastic disease",
abstract = "GTD occurs in fewer than 1 in 1200 pregnancies in the United States, but it is much more common in Asia and Latin America, where its incidence may be as high as 1 in 200 pregnancies. Risk factors for GTD include advanced or young maternal age, low socioeconomic status, and prior hydatidiform mole. Early diagnosis and prompt treatment are key to a favorable outcome, and thus recognition of the signs and symptoms of the disease is important for all physicians. Because these diseases have low incidences and occur after reproductive events, screening for them in the general population is not worthwhile. No chemopreventive agents have yet been studied in women at risk for GTD, but the oral contraceptive is a good candidate.",
author = "Freedman, {R. S.} and G. Tortolero-Luna and Pandey, {D. K.} and A. Malpica and Baker, {V. V.} and L. Whittaker and E. Johnson and Mitchell, {M. F.}",
year = "1996",
month = "7",
day = "1",
language = "English (US)",
volume = "23",
pages = "545--571",
journal = "Obstetrics and Gynecology Clinics of North America",
issn = "0889-8545",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Gestational trophoblastic disease

AU - Freedman, R. S.

AU - Tortolero-Luna, G.

AU - Pandey, D. K.

AU - Malpica, A.

AU - Baker, V. V.

AU - Whittaker, L.

AU - Johnson, E.

AU - Mitchell, M. F.

PY - 1996/7/1

Y1 - 1996/7/1

N2 - GTD occurs in fewer than 1 in 1200 pregnancies in the United States, but it is much more common in Asia and Latin America, where its incidence may be as high as 1 in 200 pregnancies. Risk factors for GTD include advanced or young maternal age, low socioeconomic status, and prior hydatidiform mole. Early diagnosis and prompt treatment are key to a favorable outcome, and thus recognition of the signs and symptoms of the disease is important for all physicians. Because these diseases have low incidences and occur after reproductive events, screening for them in the general population is not worthwhile. No chemopreventive agents have yet been studied in women at risk for GTD, but the oral contraceptive is a good candidate.

AB - GTD occurs in fewer than 1 in 1200 pregnancies in the United States, but it is much more common in Asia and Latin America, where its incidence may be as high as 1 in 200 pregnancies. Risk factors for GTD include advanced or young maternal age, low socioeconomic status, and prior hydatidiform mole. Early diagnosis and prompt treatment are key to a favorable outcome, and thus recognition of the signs and symptoms of the disease is important for all physicians. Because these diseases have low incidences and occur after reproductive events, screening for them in the general population is not worthwhile. No chemopreventive agents have yet been studied in women at risk for GTD, but the oral contraceptive is a good candidate.

UR - http://www.scopus.com/inward/record.url?scp=0029976680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029976680&partnerID=8YFLogxK

M3 - Review article

C2 - 8784889

AN - SCOPUS:0029976680

VL - 23

SP - 545

EP - 571

JO - Obstetrics and Gynecology Clinics of North America

JF - Obstetrics and Gynecology Clinics of North America

SN - 0889-8545

IS - 2

ER -